Predinisone

Phase 2Small molecule

FFirst Affiliated Hospital of Zhejiang University

Predinisone is one of 3 small molecule programs targeting Olverembatinib. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OlverembatinibRecruiting

OlverembatinibPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Olverembatinib

#DrugCompanyPhaseTrials

Luye

Ascentage Pharma Group Inc.

Phase 3

8 2

Venclexta

AbbVie

Phase 2

3 3

Predinisone

FFirst Affiliated Hospital of Zhejiang University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Olverembatinib

NCT06754267

Clinical

Trials by Indication[1]

Olverembatinib1 trial

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06754267·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Predinisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Predinisone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Predinisone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Zhejiang University

Predinisone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Olverembatinib1 trial

References

Drug Info

Quick Facts

Related News